InMed Pharmaceuticals (INM) Q2 2024 Annual Earnings
INM·Reported September 27, 2024·Before market open
InMed Pharmaceuticals reported Q2 2024 revenue of $938.5K, missed analyst consensus of $1.8M by $851.5K. Diluted EPS came in at $-3.80.
Revenue
$938.5Kmissed by $851.5K
Consensus: $1.8MDiluted EPS
$-3.80
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about InMed Pharmaceuticals's Q2 2024 earnings report.
InMed Pharmaceuticals (INM) reported Q2 2024 earnings on September 27, 2024 before market open.
InMed Pharmaceuticals reported revenue of $938.5K and diluted EPS of $-3.80 for Q2 2024.
Revenue missed the consensus estimate of $1.8M by $851.5K.
You can read the 10-K periodic report (0001213900-24-082843) directly on SEC EDGAR. The filing index links above go to sec.gov.